CO2020009524A2 - Formulación de adenovirus del grupo b - Google Patents
Formulación de adenovirus del grupo bInfo
- Publication number
- CO2020009524A2 CO2020009524A2 CONC2020/0009524A CO2020009524A CO2020009524A2 CO 2020009524 A2 CO2020009524 A2 CO 2020009524A2 CO 2020009524 A CO2020009524 A CO 2020009524A CO 2020009524 A2 CO2020009524 A2 CO 2020009524A2
- Authority
- CO
- Colombia
- Prior art keywords
- adenovirus
- group
- formulation
- glycerol
- ethanol
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente descripción proporciona una formulación líquida adecuada para un adenovirus del grupo B, que comprende: a) un adenovirus del grupo B, tal como el adenovirus del grupo B competente para replicación, b) 15 a 25 % v/v de glicerol, por ejemplo 16, 17, 18, 19, 20, 21 % v/v de glicerol; y c) 0.1 a 1.5 % v/v de etanol, por ejemplo 0.2-1 %, tal como 1 % v/v de etanol; y d) un tampón, y e) opcionalmente un aminoácido, en donde el pH de la formulación está en el intervalo de 8.0 a 9.6, y uso del mismo en el tratamiento, en particular en el tratamiento del cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1801614.7A GB201801614D0 (en) | 2018-01-31 | 2018-01-31 | Formulation |
| PCT/EP2019/052398 WO2019149829A1 (en) | 2018-01-31 | 2019-01-31 | Group b adenovirus-containing formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020009524A2 true CO2020009524A2 (es) | 2020-08-21 |
Family
ID=61558316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0009524A CO2020009524A2 (es) | 2018-01-31 | 2020-07-30 | Formulación de adenovirus del grupo b |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11998580B2 (es) |
| EP (1) | EP3746128A1 (es) |
| JP (2) | JP7491843B2 (es) |
| KR (1) | KR102794512B1 (es) |
| CN (1) | CN111727062A (es) |
| AU (1) | AU2019214397A1 (es) |
| BR (1) | BR112020014248A2 (es) |
| CA (1) | CA3088350A1 (es) |
| CL (1) | CL2020001821A1 (es) |
| CO (1) | CO2020009524A2 (es) |
| EA (1) | EA202091318A1 (es) |
| GB (1) | GB201801614D0 (es) |
| IL (1) | IL276011B (es) |
| MX (1) | MX2020007495A (es) |
| PH (1) | PH12020551057A1 (es) |
| SG (1) | SG11202005746RA (es) |
| WO (1) | WO2019149829A1 (es) |
| ZA (1) | ZA202003615B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035875T2 (hu) | 2013-10-25 | 2018-06-28 | Psioxus Therapeutics Ltd | Heterológ géneket tartalmazó onkolitikus adenovírusok |
| HRP20200439T1 (hr) | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| BR112018012180A2 (pt) | 2015-12-17 | 2018-12-04 | Psioxus Therapeutics Ltd | vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| US20250262268A1 (en) * | 2020-08-18 | 2025-08-21 | New York Genome Center, Inc. | Methods and Compositions for Inhibiting Viral Infection |
| GB202102049D0 (en) | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
| CN114601838B (zh) * | 2022-04-29 | 2023-10-27 | 广东龙帆生物科技有限公司 | 一种azd8055在制备用于抗腺病毒感染的药物中的用途 |
| CN117618549A (zh) * | 2022-08-09 | 2024-03-01 | 康希诺生物股份公司 | 一种基于黑猩猩腺病毒载体疫苗液体制剂及制备方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0170269A3 (en) | 1984-08-02 | 1987-09-23 | Kao Corporation | Medicated cosmetic compositions |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| DE19648650C2 (de) | 1996-01-29 | 1998-07-02 | Schering Ag | Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| CN101618049A (zh) | 1997-10-09 | 2010-01-06 | 威尔斯塔特生物公司 | 使用病毒来治疗赘生物 |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| JP4802366B2 (ja) | 1999-02-22 | 2011-10-26 | トランスジェン・ソシエテ・アノニム | 精製ウイルス調製物の取得方法 |
| WO2000061726A1 (fr) | 1999-04-09 | 2000-10-19 | Aventis Pharma S.A. | Composition destinee a la conservation d'adenovirus recombinants infectieux |
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| US7456009B2 (en) * | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| MXPA06004035A (es) | 2003-10-16 | 2006-08-31 | Micromet Ag | Aglutinantes cd3 de-inmunizados multi-especificos. |
| BRPI0510475B8 (pt) | 2004-05-26 | 2021-05-25 | Bayer Pharma AG | adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus |
| US20060205080A1 (en) | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
| CN1961961B (zh) | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| US20110034560A1 (en) | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| CN101381742A (zh) | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| NO2748201T3 (es) | 2011-08-23 | 2018-05-12 | ||
| CN108771655A (zh) * | 2011-10-28 | 2018-11-09 | 诚信生物公司 | 含有氨基酸的蛋白质制剂 |
| RU2737765C2 (ru) | 2012-05-04 | 2020-12-02 | Пфайзер Инк. | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| CA2914790C (en) * | 2013-06-14 | 2024-02-27 | Psioxus Therapeutics Limited | A dosing regime and formulations for type b adenoviruses |
| WO2015040234A1 (en) | 2013-09-23 | 2015-03-26 | Crucell Holland B.V. | Adenovirus formulations |
| GB201318793D0 (en) | 2013-10-24 | 2013-12-11 | Plaquetec Ltd | Vascular Biomarkers |
| HUE035875T2 (hu) | 2013-10-25 | 2018-06-28 | Psioxus Therapeutics Ltd | Heterológ géneket tartalmazó onkolitikus adenovírusok |
| PL3560954T3 (pl) | 2014-04-03 | 2021-12-13 | Igm Biosciences, Inc. | Zmodyfikowany łańcuch J |
| EP3186366A2 (en) | 2014-08-27 | 2017-07-05 | Psioxus Therapeutics Limited | A process for the production of adenovirus |
| HRP20200439T1 (hr) * | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| CN109312364A (zh) | 2016-03-18 | 2019-02-05 | 河谷细胞有限公司 | 用于感染树突状细胞的多模式载体 |
| WO2018075978A1 (en) | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
-
2018
- 2018-01-31 GB GBGB1801614.7A patent/GB201801614D0/en not_active Ceased
-
2019
- 2019-01-31 EP EP19706388.6A patent/EP3746128A1/en active Pending
- 2019-01-31 SG SG11202005746RA patent/SG11202005746RA/en unknown
- 2019-01-31 CA CA3088350A patent/CA3088350A1/en active Pending
- 2019-01-31 IL IL276011A patent/IL276011B/en unknown
- 2019-01-31 JP JP2020538999A patent/JP7491843B2/ja active Active
- 2019-01-31 MX MX2020007495A patent/MX2020007495A/es unknown
- 2019-01-31 CN CN201980008189.XA patent/CN111727062A/zh active Pending
- 2019-01-31 AU AU2019214397A patent/AU2019214397A1/en not_active Abandoned
- 2019-01-31 BR BR112020014248-4A patent/BR112020014248A2/pt not_active IP Right Cessation
- 2019-01-31 US US16/965,549 patent/US11998580B2/en active Active
- 2019-01-31 WO PCT/EP2019/052398 patent/WO2019149829A1/en not_active Ceased
- 2019-01-31 KR KR1020207022489A patent/KR102794512B1/ko active Active
- 2019-01-31 EA EA202091318A patent/EA202091318A1/ru unknown
-
2020
- 2020-06-17 ZA ZA2020/03615A patent/ZA202003615B/en unknown
- 2020-07-08 CL CL2020001821A patent/CL2020001821A1/es unknown
- 2020-07-09 PH PH12020551057A patent/PH12020551057A1/en unknown
- 2020-07-30 CO CONC2020/0009524A patent/CO2020009524A2/es unknown
-
2024
- 2024-01-22 JP JP2024007320A patent/JP2024045278A/ja active Pending
- 2024-04-18 US US18/639,598 patent/US20240398879A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210121512A1 (en) | 2021-04-29 |
| CL2020001821A1 (es) | 2020-11-06 |
| SG11202005746RA (en) | 2020-08-28 |
| EP3746128A1 (en) | 2020-12-09 |
| IL276011A (en) | 2020-08-31 |
| GB201801614D0 (en) | 2018-03-14 |
| US20240398879A1 (en) | 2024-12-05 |
| MX2020007495A (es) | 2020-11-12 |
| WO2019149829A1 (en) | 2019-08-08 |
| JP2024045278A (ja) | 2024-04-02 |
| US11998580B2 (en) | 2024-06-04 |
| CN111727062A (zh) | 2020-09-29 |
| IL276011B (en) | 2022-08-01 |
| BR112020014248A2 (pt) | 2020-12-15 |
| KR20200115525A (ko) | 2020-10-07 |
| JP2021512054A (ja) | 2021-05-13 |
| JP7491843B2 (ja) | 2024-05-28 |
| CA3088350A1 (en) | 2019-08-08 |
| ZA202003615B (en) | 2021-09-29 |
| AU2019214397A1 (en) | 2020-08-13 |
| EA202091318A1 (ru) | 2020-11-13 |
| PH12020551057A1 (en) | 2021-08-23 |
| KR102794512B1 (ko) | 2025-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020009524A2 (es) | Formulación de adenovirus del grupo b | |
| UY38221A (es) | Inhibidores de proteínas ras con g12c mutantes | |
| CL2021003477A1 (es) | Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8 | |
| MX2023008779A (es) | Adenovirus armado con un activador biespecifico de linfocitos t. | |
| CL2020002797A1 (es) | Composiciones sólidas que comprenden un agonista de glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
| NI201700073A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| PE20200006A1 (es) | Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap | |
| CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
| CL2018000222A1 (es) | Nueva combinación para el uso en el tratamiento del cáncer | |
| CL2016002516A1 (es) | “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct | |
| MX2020001083A (es) | Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial. | |
| MX2020011339A (es) | Polímero catiónico y uso para suministro de biomolecúla. | |
| ES2543957T3 (es) | Nueva composición farmacéutica para el tratamiento de infecciones fúngicas | |
| UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
| CL2009001215A1 (es) | Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer. | |
| MX2014000066A (es) | Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana. | |
| CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| CL2019001550A1 (es) | Fenytoina tópica para uso en el tratamiento del dolor neuropático periférico. | |
| BR112022013204A2 (pt) | Usos de uma composição e de uma preparação combinada | |
| ECSP24028472A (es) | Administración facilitada de formulaciones concentradas de anticuerpos mediante el uso de hialuronidasa | |
| CL2020000221A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| AR109798A1 (es) | Composición para el tratamiento capilar | |
| CO2024000581A2 (es) | Comprimido que comprende una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
| CL2012003119A1 (es) | Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre. | |
| CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. |